| Pharmaceutical Information |
| Drug Name |
Imiglucerase |
| Drug ID |
BADD_D01138 |
| Description |
Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues. |
| Indications and Usage |
For the treatment of Gaucher's disease (deficiency in glucocerebrosidase) |
| Marketing Status |
approved |
| ATC Code |
A16AB02 |
| DrugBank ID |
DB00053
|
| KEGG ID |
D03020
|
| MeSH ID |
C090568
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0QW9H
|
| NDC Product Code |
67643-0020; 58468-4663 |
| UNII |
Q6U6J48BWY
|
| Synonyms |
imiglucerase | Cerezyme |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
154248-97-2 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
